Haemonetics Statistics
Total Valuation
Haemonetics has a market cap or net worth of $4.13 billion. The enterprise value is $5.08 billion.
| Market Cap | 4.13B |
| Enterprise Value | 5.08B |
Important Dates
The last earnings date was Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Haemonetics has 45.50 million shares outstanding. The number of shares has decreased by -6.48% in one year.
| Current Share Class | 45.50M |
| Shares Outstanding | 45.50M |
| Shares Change (YoY) | -6.48% |
| Shares Change (QoQ) | -1.12% |
| Owned by Insiders (%) | 1.30% |
| Owned by Institutions (%) | 110.07% |
| Float | 44.89M |
Valuation Ratios
The trailing PE ratio is 44.10 and the forward PE ratio is 16.77. Haemonetics's PEG ratio is 1.55.
| PE Ratio | 44.10 |
| Forward PE | 16.77 |
| PS Ratio | 3.06 |
| Forward PS | 2.88 |
| PB Ratio | 4.93 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 14.19 |
| P/OCF Ratio | 12.59 |
| PEG Ratio | 1.55 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.16, with an EV/FCF ratio of 17.45.
| EV / Earnings | 52.77 |
| EV / Sales | 3.76 |
| EV / EBITDA | 14.16 |
| EV / EBIT | 19.94 |
| EV / FCF | 17.45 |
Financial Position
The company has a current ratio of 3.08, with a Debt / Equity ratio of 1.40.
| Current Ratio | 3.08 |
| Quick Ratio | 1.67 |
| Debt / Equity | 1.40 |
| Debt / EBITDA | 3.18 |
| Debt / FCF | 4.03 |
| Interest Coverage | 9.30 |
Financial Efficiency
Return on equity (ROE) is 11.20% and return on invested capital (ROIC) is 10.42%.
| Return on Equity (ROE) | 11.20% |
| Return on Assets (ROA) | 6.60% |
| Return on Invested Capital (ROIC) | 10.42% |
| Return on Capital Employed (ROCE) | 12.12% |
| Weighted Average Cost of Capital (WACC) | 5.91% |
| Revenue Per Employee | $449,323 |
| Profits Per Employee | $32,000 |
| Employee Count | 3,009 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 1.65 |
Taxes
In the past 12 months, Haemonetics has paid $34.15 million in taxes.
| Income Tax | 34.15M |
| Effective Tax Rate | 26.18% |
Stock Price Statistics
The stock price has increased by +68.52% in the last 52 weeks. The beta is 0.52, so Haemonetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.52 |
| 52-Week Price Change | +68.52% |
| 50-Day Moving Average | 78.92 |
| 200-Day Moving Average | 69.48 |
| Relative Strength Index (RSI) | 70.81 |
| Average Volume (20 Days) | 753,618 |
Short Selling Information
The latest short interest is 2.92 million, so 6.42% of the outstanding shares have been sold short.
| Short Interest | 2.92M |
| Short Previous Month | 2.91M |
| Short % of Shares Out | 6.42% |
| Short % of Float | 6.51% |
| Short Ratio (days to cover) | 4.59 |
Income Statement
In the last 12 months, Haemonetics had revenue of $1.35 billion and earned $96.29 million in profits. Earnings per share was $2.06.
| Revenue | 1.35B |
| Gross Profit | 802.16M |
| Operating Income | 254.82M |
| Pretax Income | 130.44M |
| Net Income | 96.29M |
| EBITDA | 358.79M |
| EBIT | 254.82M |
| Earnings Per Share (EPS) | $2.06 |
Balance Sheet
The company has $224.52 million in cash and $1.17 billion in debt, with a net cash position of -$949.64 million or -$20.87 per share.
| Cash & Cash Equivalents | 224.52M |
| Total Debt | 1.17B |
| Net Cash | -949.64M |
| Net Cash Per Share | -$20.87 |
| Equity (Book Value) | 837.10M |
| Book Value Per Share | 18.41 |
| Working Capital | 547.60M |
Cash Flow
In the last 12 months, operating cash flow was $328.15 million and capital expenditures -$36.93 million, giving a free cash flow of $291.22 million.
| Operating Cash Flow | 328.15M |
| Capital Expenditures | -36.93M |
| Depreciation & Amortization | 103.97M |
| Net Borrowing | -56.25M |
| Free Cash Flow | 291.22M |
| FCF Per Share | $6.40 |
Margins
Gross margin is 59.33%, with operating and profit margins of 18.85% and 7.12%.
| Gross Margin | 59.33% |
| Operating Margin | 18.85% |
| Pretax Margin | 9.65% |
| Profit Margin | 7.12% |
| EBITDA Margin | 26.54% |
| EBIT Margin | 18.85% |
| FCF Margin | 21.54% |
Dividends & Yields
Haemonetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 6.48% |
| Shareholder Yield | 6.48% |
| Earnings Yield | 2.33% |
| FCF Yield | 7.05% |
Analyst Forecast
The average price target for Haemonetics is $96.90, which is 6.72% higher than the current price. The consensus rating is "Buy".
| Price Target | $96.90 |
| Price Target Difference | 6.72% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | 5.80% |
| EPS Growth Forecast (3Y) | 8.66% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 3, 2012. It was a forward split with a ratio of 2:1.
| Last Split Date | Dec 3, 2012 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Haemonetics has an Altman Z-Score of 2.58 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.58 |
| Piotroski F-Score | 7 |